IMR Press / FBL / Volume 14 / Issue 6 / DOI: 10.2741/3371

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Combined microPET/CT for imaging of hepatocellular carcinoma in mice
Show Less
1 Institute of Radiology, Hannover Medical School, Hannover, Germany
2 Department of Pharmaceutical Research and Medical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany
3 Institute of Pathology, Viersen, Germany
Academic Editor:Fabian Kiessling
Front. Biosci. (Landmark Ed) 2009, 14(6), 2193–2202;
Published: 1 January 2009
(This article belongs to the Special Issue Molecular imaging in cancer)

The EGF-transgenic mouse is a genetic model of hepatocellular carcinoma that allows for a comprehensive study of signal pathways, molecular interactions and the evaluation of novel therapeutic concepts. In this regard, non-invasive imaging tools for serial in-vivo monitoring of tumor load and growth are highly desirable. This study therefore aimed at demonstrating the feasibility of non-invasive in-vivo imaging of primary liver malignancies in mice using combined contrast-enhanced microCT and F-18 FDG microPET. In our murine disease model, microCT enabled imaging of primary liver tumors down to a lesional diameter of 0.9 mm. F-18 FDG tumor-to-non-tumor ratio of HCCs was observed to be dependent on lesion size and linked to overpression of glucose transporters and hexokinase isoenzymes as determined by gene expression studies. Histopathologic analyses indicated an increased cellular dedifferentiation with increase lesion size, as well.

Back to top